144 related articles for article (PubMed ID: 34452645)
21. A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study.
Botson JK; Tesser JRP; Bennett R; Kenney HM; Peloso PM; Obermeyer K; Song Y; LaMoreaux B; Zhao L; Xin Y; Chamberlain J; Ramanathan S; Weinblatt ME; Peterson J
Arthritis Res Ther; 2022 Aug; 24(1):208. PubMed ID: 36008814
[TBL] [Abstract][Full Text] [Related]
22. Unclosing Premature Mortality Gap Among Patients With Gout in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors.
McCormick N; Lin K; Yokose C; Lu N; Zhang Y; Choi HK
Arthritis Care Res (Hoboken); 2024 May; 76(5):691-702. PubMed ID: 38191784
[TBL] [Abstract][Full Text] [Related]
23. Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort.
Singh JA; Yang S; Saag KG
J Rheumatol; 2020 Mar; 47(3):449-460. PubMed ID: 31416925
[TBL] [Abstract][Full Text] [Related]
24. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Ann Rheum Dis; 2017 Sep; 76(9):1522-1528. PubMed ID: 28314755
[TBL] [Abstract][Full Text] [Related]
25. Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial.
Stamp LK; O'Donnell JL; Frampton C; Drake JM; Zhang M; Chapman PT
Arthritis Rheum; 2013 Jun; 65(6):1636-42. PubMed ID: 23681955
[TBL] [Abstract][Full Text] [Related]
26. Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout.
Broadwell A; Albert JA; Padnick-Silver L; LaMoreaux B
Rheumatol Ther; 2022 Dec; 9(6):1549-1558. PubMed ID: 36136270
[TBL] [Abstract][Full Text] [Related]
27. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
Yeo E; Palmer SC; Chapman PT; Frampton C; Stamp LK
Intern Med J; 2019 Jul; 49(7):838-842. PubMed ID: 30426652
[TBL] [Abstract][Full Text] [Related]
28. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
[TBL] [Abstract][Full Text] [Related]
29. Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topless R; Noorbaloochi S; Merriman TR; Singh JA
Semin Arthritis Rheum; 2022 Oct; 56():152057. PubMed ID: 35835008
[TBL] [Abstract][Full Text] [Related]
30. Serum urate and incidence of kidney disease among veterans with gout.
Krishnan E; Akhras KS; Sharma H; Marynchenko M; Wu E; Tawk RH; Liu J; Shi L
J Rheumatol; 2013 Jul; 40(7):1166-72. PubMed ID: 23678154
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for incident hyperuricemia during mid-adulthood in African American and white men and women enrolled in the ARIC cohort study.
McAdams-DeMarco MA; Law A; Maynard JW; Coresh J; Baer AN
BMC Musculoskelet Disord; 2013 Dec; 14():347. PubMed ID: 24330409
[TBL] [Abstract][Full Text] [Related]
32. Hypouricemia and Mortality Risk in the US General Population.
D'Silva KM; Yokose C; Lu N; McCormick N; Lee H; Zhang Y; Choi HK
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1171-1179. PubMed ID: 33026684
[TBL] [Abstract][Full Text] [Related]
33. Allopurinol Dose Escalation and Mortality Among Patients With Gout: A National Propensity-Matched Cohort Study.
Coburn BW; Michaud K; Bergman DA; Mikuls TR
Arthritis Rheumatol; 2018 Aug; 70(8):1298-1307. PubMed ID: 29513934
[TBL] [Abstract][Full Text] [Related]
34. Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Rheumatology (Oxford); 2018 Dec; 57(12):2183-2189. PubMed ID: 30107437
[TBL] [Abstract][Full Text] [Related]
35. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Ann Rheum Dis; 2017 Dec; 76(12):2065-2070. PubMed ID: 28830881
[TBL] [Abstract][Full Text] [Related]
36. Association between being African-American, serum urate levels and the risk of developing hyperuricemia: findings from the Coronary Artery Risk Development in Young Adults cohort.
Gaffo AL; Jacobs DR; Lewis CE; Mikuls TR; Saag KG
Arthritis Res Ther; 2012 Jan; 14(1):R4. PubMed ID: 22225548
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Rates of Lower Extremity Amputation in Patients With and Without Gout in the US Department of Veterans Affairs Health System.
Mikuls TR; Soto Q; Petro A; Helget L; Roul P; Sayles H; Cope B; Neogi T; LaMoreaux B; O'Dell JR; England BR
JAMA Netw Open; 2022 Jan; 5(1):e2142347. PubMed ID: 34989795
[TBL] [Abstract][Full Text] [Related]
38. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
39. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study.
Roughley M; Sultan AA; Clarson L; Muller S; Whittle R; Belcher J; Mallen CD; Roddy E
Arthritis Res Ther; 2018 Oct; 20(1):243. PubMed ID: 30376864
[TBL] [Abstract][Full Text] [Related]
40. Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements.
Stamp LK; Morillon MB; Taylor WJ; Dalbeth N; Singh JA; Lassere M; Christensen R
J Rheumatol; 2018 Mar; 45(3):419-424. PubMed ID: 29247147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
